Other Information.
+Added: On June 8, 2022, we entered into an amendment to our lease agreement, dated November 4, 2019, between us and Witman Properties, L.L.C.
+Added: and Alexander Road at Davanne, L.L.C.
+Added: (collectively, the “Landlord”).
+Added: Pursuant to the amendment, we extended the expiration date of the lease from January 31, 2023 to January 31, 2026.
+Added: Commencing with the extension term on February 1, 2023, our base rent will be approximately $0.6 million per year, or approximately $1.7 million in total during the extension term.
+Added: The foregoing summary of the lease amendment is qualified in its entirety by reference to the lease amendment, a copy of which is filed as Exhibit 10.2 to this Quarterly Report.
The following exhibits are filed as part of this report:
2 unchanged sentences
001-38079), filed with the SEC on May 18, 2017).
−Removed: Loan Agreement, dated as of March 7, 2022, by and among UroGen Pharma Ltd.
−Removed: (the “Company”), UroGen Pharma, Inc., as the borrower, and certain direct and indirect subsidiaries of the Company party thereto from time to time, as guarantors, BPCR Limited Partnership, as a lender, BioPharma Credit Investments V (Master) LP, as a lender, and BioPharma Credit PLC, as collateral agent for the lenders.
−Removed: Manufacturing & Supply Agreement, dated as of April 24, 2020 and amended as of March 2, 2022, by and between UroGen Pharma Ltd.
−Removed: and Cenexi-Laboratoires Thissen s.a.
+Added: Ur oGen Pharma Ltd.
+Added: 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant ’s Current Report on Form 8-K (File No.
+Added: Amendment to Lease Agreement, dated June 8, 2022, by and between the Registrant and Witman Properties, L.L.C.
+Added: and Alexander Road at Davanne, L.L.C.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
−Removed: Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+Added: Management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
UroGen Pharma Ltd.
+Added: August 11, 2022
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
+Added: August 11, 2022
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.